Disruptions due to COVID-19 paired with a slew of new guidance from regulatory bodies has catapulted the clinical trial industry into a period of digital transformation.1 More sponsors and CROs are beginning to adopt decentralized solutions and embrace digital workflows, yet informed consent continues to rely heavily on paper-based processes. Lots and lots of paper.
If you’re wondering how much paper, consider a recent study that found that the average 1,500-bed hospital prints over eight million pages per month at the cost of four cents per page.2 Not including printing equipment, that adds up to nearly $3.8 million each year.
And while a majority of healthcare organizations are digitizing their processes with eClinical solutions, 76% still admit to printing their consent forms.2
Consent is a critical part of the patient journey. Ensuring patients are fully informed and willing to participate in a trial is an ongoing process. Study and site managers must confirm that patients receive all of the necessary information to make a free and informed choice before consenting to participate in a study - and continuously throughout the trial. Only then can clinicians fulfill the legal and ethical responsibility of their trials while bringing their medical breakthroughs to market.
We will explore the role consent plays in the success of your trials and how the industry is shifting towards greater adoption of eConsent to strengthen patient comprehension, adherence, and retention.
To learn more about Medrio, visit their Clinical Leader page.